| dc.description.abstract | Due to widespread anti-malarial drug resistance in many countries, Kenya
included, artemisinin-based Combination Therapy (ACT) has been adopted as the most
effective treatment option against malaria. Artemether-lumefantrine (AL) is the first-line ACT
for treatment of uncomplicated malaria in Kenya, while quinine is preferred for complicated
and severe malaria. Information on the providers' knowledge and practices prior to or during
AL and quinine implementation is scanty. The current study evaluated providers' knowledge
and practices of treatment policy and dosing regimens with AL and quinine in the public,
private and not-for-profit drug outlets. Methods A cross-sectional survey using three-stage
sampling of 288 (126 public, 96 private and 66 not-for-profits) providers in drug outlets was
conducted in western Kenya in two Plasmodium falciparum-endemic regions with varying … | en_US |
